Clinical Trial Update: Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis [Phase 2]

View source ↗

Summary

Phase 2 study of MP4CO for vaso-occlusive crises in sickle cell disease has been withdrawn. Sponsor Sangart reported the study status as withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemoglobin Sc Disease
• Sickle Cell Disease

Drugs mentioned

• MP4CO

Snippet

Sponsor: Sangart | Conditions: Anemia, Sickle Cell, Sickle Cell Anemia | Phase 2 | Status: WITHDRAWN